DCGI seeking more data for emergency use authorization will not impact timing for vaccine ro- The New Indian Express


NEW DELHI: Applications from Bharat Biotech, Serum Institute and Pfizer requesting emergency use permits for their COVID-19 vaccines are being examined, the Center said on Tuesday, stating that DCGI drug regulator seeking more data from these companies will not impact on the vaccine out of time.

These requests to the Comptroller General of Drugs of India are being examined by the CDSCO’s COVID-19 expert committee on authorization for emergency use, said Dr. VK Paul, NITI Aayog (Health) member.

“This situation has been considered in advance because it is an emergency use authorization. There should be more than reasonable satisfaction with the safety, immunogenicity and effectiveness of the vaccine,” he told reporters when asked about the vaccine. DCGI requesting more information from companies for the emergency use of their vaccines.

“Applications are being reviewed on a scientific basis, using scientific frameworks that are aligned globally and ensuring that the vaccine is safe, adequately immunogenic and effective in reducing the incidence of COVID-19 disease in humans. This independent process is ongoing. “

“I would like to mention that when we talk about these processes, we are not talking about an individual or three people. They are scientists, epidemiologists, clinicians, scientists, pharmacologists, biologists. They make the decision based on science.” said Paul. said.

Speaking about post-immunization adverse events (EFSA), Paul said every time a new drug or vaccine is introduced into the country, there is a stage 4 phase of the clinical trial, also known as post-market surveillance.

At this stage, vaccine manufacturers systematically monitor and monitor the effects of the vaccine after it has been passed.

“If a vaccine or two comes after obtaining emergency use authorization, you should have full faith that the vaccine is scientifically proven, meets global standards, safe and effective,” he said.

Responding to a question about AEFI for the COVID-19 vaccine, Paul said: ‚ÄúThis is an adult vaccine. Our AEFI system was intended for children and women and these vaccinations take place in a certain way, starting with hospitals and then in communities. But when dealing with adults, certain practical issues need to be addressed. “

“Secondly, these vaccinations are in several new platforms that bring complexity. Moreover, if an emergency use permit is granted, it requires more responsibility. Finally, there are always new aspects, side effects, situations that need to be taken into account. .

Above all, a large number of beneficiaries and target groups are to be addressed in a short period of time in a mission mode, “he said.

“Therefore, it needs to be based on the standard principles of AEFI and be specific to the fuller size of the requirements of this particular set of vaccines.”

Regarding the development of the vaccine, said Paul, this week, DCGI granted authorization to conduct human phase 1 and 2 clinical trials of the COVID-19 vaccine developed by Gennova Biopharmaceuticals Ltd in Pune, in collaboration with HDT, USA.

“An important part of this vaccine is different from the Pfizer vaccine or others, this vaccine, if it exists, will be able to be maintained in a normal cold chain condition in a normal refrigerator. This is an important thing,” he said. he said.

He said at the moment, six vaccines are undergoing clinical trials in India.

These are the ones developed by Bharat Biotech in collaboration with ICMR; the second by Zydus Cadila; the third of Gennova; The Oxford vaccine, whose study is being conducted by the Serum Institute of India; The Sputnik V vaccine, which is manufactured by Dr. Reddy’s Lab, Hyderabad, in collaboration with the Gamaleya National Center in Russia; and the sixth produced by Biological E Ltd, Hyderabad, in collaboration with MIT, USA. E. biological